Abstract
The clinical benefits of the MammaPrint® signature for breast cancer is well documented; however, how these genes are related to cell cycle perturbation have not been well determined. Our single-cell transcriptome mapping (algorithm) provides details into the fine perturbation of all individual genes during a cell cycle, providing a view of the cell-cycle-phase specific landscape of any given human genes. Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel derived its clinical prognosis power from measuring the cell cycle activity of specific breast cancer samples. Such cell cycle phase index of the MammaPrint® signature suggested that measurement of the cell cycle index from tumors could be developed into a prognosis tool for various types of cancer beyond breast cancer, potentially improving therapy through targeting a specific phase of the cell cycle of cancer cells.
Original language | English (US) |
---|---|
Pages (from-to) | 33290-33301 |
Number of pages | 12 |
Journal | Oncotarget |
Volume | 9 |
Issue number | 70 |
DOIs | |
State | Published - Sep 1 2018 |
Externally published | Yes |
Keywords
- Cell cycle
- Cell cycle phase
- Cell-cycle-staged therapy
- Single-cell
- Transcriptome
ASJC Scopus subject areas
- Oncology